--- title: "XORTX Therapeutics files $2,500,000 paid promotion agreement with IR Agency" url: "https://aibio.space/news/xortx-therapeutics-files-2-500-000-paid-promotion-agreement-ir-agency/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-04" section: "Listings" tickers: "NASDAQ:XRTX" source: "https://www.sec.gov/Archives/edgar/data/1729214/000118518526003845/xortxex99-1.htm" summary: "The consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are" --- By the aibio.space news desk. Sources - [XORTX Therapeutics Inc. 6-K (2026-09-04)](https://www.sec.gov/Archives/edgar/data/1729214/000118518526003845/xortxex99-1.htm) [XRTX](https://aibio.space/companies/xortx-therapeutics/) 2026-09-04 # XORTX Therapeutics files $2,500,000 paid promotion agreement with IR Agency Tickers [XRTX](https://aibio.space/companies/xortx-therapeutics/) The consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are promotional. ## Key facts - **Company**: XORTX Therapeutics Inc. (NASDAQ: XRTX) - **News type**: Listings - **Primary source**: [XORTX Therapeutics Inc. 6-K (2026-09-04)](https://www.sec.gov/Archives/edgar/data/1729214/000118518526003845/xortxex99-1.htm) *A stone federal courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* XORTX Therapeutics Inc. (Nasdaq: [XRTX](https://aibio.space/companies/xortx-therapeutics/)) filed a consulting agreement with IR Agency LLC as an exhibit to a Form 6-K dated September 4, 2026. The agreement covers marketing and advertising services to communicate information about XORTX to the financial community, including creating company profiles and media distribution. The services are described in the agreement as promotional, and XORTX is paying for a capped number of news releases, not for any result. ## The fee and what it buys Under the compensation section, XORTX is to pay IR Agency $2,500,000 in cash by bank wire by September 2, 2026. The fee covers marketing of news distribution during a maximum of 10 news releases over a three-month term starting September 3, 2026. The agreement says the fees are fully earned on receipt and are strictly non-refundable under any circumstances, including termination, dissatisfaction or results. XORTX also waives any right to a refund, offset or chargeback. ## Termination Either party may terminate the agreement, with or without cause, at any time by written notice. If XORTX ends it during the term for any reason, it is not entitled to a return of any of the compensation. XORTX may cancel before any new quarter begins, and it may ask to extend the agreement during months when no news distribution is performed. IR Agency may also terminate if XORTX files for bankruptcy, becomes insolvent or is in material breach, and XORTX would still receive no refund. ## What the consultant disclaims IR Agency states that it carries no professional licenses. Under the agreement it will not participate in discussions or negotiations with potential investors, will not solicit orders, and will not make recommendations or give investment advice. The agreement says the services are not exclusive, so IR Agency may perform similar work for other clients. It makes no representation about how the market will respond to the releases and does not guarantee that trading volume will rise or that the share price will rise. It says all market risk falls on XORTX. ## The disclosure clause A section titled Paid Promotion Disclosure (SEC 17(b)) allows IR Agency to include disclosures required by securities laws, including compensation disclosure, in the material it distributes. XORTX agrees not to restrict or alter those disclosures. ## Who signed, and the legal terms IR Agency LLC gives a Newark, New Jersey address. Rafael Pereira signed for it, and Mika Grasso signed for XORTX as Co-Chief Executive Officer, with the date 9/2/2026. The agreement says XORTX will not sue IR Agency over any failure of trading volume or share price to rise. XORTX must indemnify IR Agency against claims and regulatory investigations arising from the advertising, including defense costs. IR Agency's liability is capped at the compensation paid, except for deliberate fault or gross negligence, and disputes go to binding arbitration administered by the AAA in New Jersey. IR Agency may also immediately suspend or terminate the services if continued work could expose it to legal, regulatory or reputational risk, with no refund. XORTX also warrants that the company information it supplies is not part of any illegal offering, pump-and-dump, scalping or touting scheme. IR Agency relies on XORTX's press releases and latest SEC reports without independent verification. ## The company behind the payment The company's annual report on Form 20-F, filed in March 2026, says XORTX was in negotiations on what it called a significant financing initiative. It said a condition of that financing was replacing three board nominees with George Scorsis, Richard Grieve and Mika Grasso, and that the new nominees would resign if the financing were not completed. Mika Grasso is the executive who signed this agreement. This 6-K gives only the contract. It does not say why XORTX chose this service, what it expects from the releases or how the $2,500,000 relates to the company's cash. The term runs three months from September 3, 2026 unless the parties agree to extend it. The central point is plain: XORTX has committed $2,500,000 to a promotion it cannot get back, and the consultant has said in writing that it cannot promise the market will respond. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story XRTX XORTX Therapeutics Inc. NASDAQ ยท Canada Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/xortx-therapeutics-files-2-500-000-paid-promotion-agreement-ir-agency/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "XORTX Therapeutics files $2,500,000 paid promotion agreement with IR Agency", 2026-09-04, https://aibio.space/news/xortx-therapeutics-files-2-500-000-paid-promotion-agreement-ir-agency/